{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:03:12Z","timestamp":1789362192507,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10679-3","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:21:40Z","timestamp":1789359700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atrial fibrillation in transthyretin amyloid cardiomyopathy: marker of disease severity and implications for multidomain reassessment"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5005-6254","authenticated-orcid":false,"given":"Carlos M.","family":"Pe\u00f1ate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando Henriquez","family":"Italin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Dzebu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"10679_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F et al (2024) Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 390:132\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"key":"10679_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD et al (2025) Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 392:33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134","journal-title":"N Engl J Med"},{"key":"10679_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"10679_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jacc.2025.10.021","volume":"87","author":"G Spencer-Bonilla","year":"2026","unstructured":"Spencer-Bonilla G, Fan J, Cheng P et al (2026) Delayed diagnosis of transthyretin amyloid cardiomyopathy in the Veterans Health Administration. J Am Coll Cardiol 87:533\u2013545. https:\/\/doi.org\/10.1016\/j.jacc.2025.10.021","journal-title":"J Am Coll Cardiol"},{"key":"10679_CR5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","volume":"6","author":"E Donnellan","year":"2020","unstructured":"Donnellan E, Wazni OM, Hanna M et al (2020) Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol 6:1118\u20131127. https:\/\/doi.org\/10.1016\/j.jacep.2020.04.019","journal-title":"JACC Clin Electrophysiol"},{"key":"10679_CR6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaccao.2024.03.007","volume":"6","author":"R Witteles","year":"2024","unstructured":"Witteles R, Jefferies JL, Kapa S et al (2024) Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy. JACC CardioOncol 6:592\u2013598. https:\/\/doi.org\/10.1016\/j.jaccao.2024.03.007","journal-title":"JACC CardioOncol"},{"issue":"13 Suppl","key":"10679_CR7","doi-asserted-by":"publisher","first-page":"A559","DOI":"10.1016\/j.jacc.2026.02.1500","volume":"87","author":"A Suits","year":"2026","unstructured":"Suits A, Mejia AT, Wiedrick J et al (2026) Association between atrial fibrillation or flutter and outcomes in transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 87(13 Suppl):A559\u2013A560. https:\/\/doi.org\/10.1016\/j.jacc.2026.02.1500. [Conference abstract]","journal-title":"J Am Coll Cardiol"},{"key":"10679_CR8","doi-asserted-by":"publisher","unstructured":"Sperry BW, Masri A, Alexander KM et al (2026) Efficacy of acoramidis in transthyretin amyloid cardiomyopathy with and without atrial fibrillation: results from ATTRibute-CM. https:\/\/doi.org\/10.1016\/j.cardfail.2026.05.024. [Epub ahead of print] J Card Fail","DOI":"10.1016\/j.cardfail.2026.05.024"},{"key":"10679_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.amjcard.2025.06.015","volume":"254","author":"JK Skov","year":"2025","unstructured":"Skov JK, Ladefoged B, Pedersen ALD, Clemmensen TS, Nielsen JC, Poulsen SH (2025) Atrial fibrillation burden, risk factors, and prognosis in wild-type transthyretin amyloidosis cardiomyopathy. Am J Cardiol 254:85\u201393. https:\/\/doi.org\/10.1016\/j.amjcard.2025.06.015","journal-title":"Am J Cardiol"},{"key":"10679_CR10","doi-asserted-by":"publisher","first-page":"102470","DOI":"10.1016\/j.jacadv.2025.102470","volume":"5","author":"N Chan","year":"2026","unstructured":"Chan N, Brailovsky Y, Teruya S et al (2026) Atrial fibrillation\/flutter in transthyretin cardiac amyloidosis: prevalence, incidence, clinical predictors, and effect of tafamidis. JACC Adv 5:102470. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102470","journal-title":"JACC Adv"},{"key":"10679_CR11","doi-asserted-by":"publisher","first-page":"e101917","DOI":"10.7759\/cureus.101917","volume":"18","author":"CM Penate","year":"2026","unstructured":"Penate CM, Peix A, Perez A et al (2026) Atrial fibrillation in transthyretin amyloid cardiomyopathy: a marker of disease severity but not an independent predictor of mortality. Cureus 18:e101917. https:\/\/doi.org\/10.7759\/cureus.101917","journal-title":"Cureus"},{"key":"10679_CR12","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/j.hrthm.2025.04.020","volume":"22","author":"D Yakabe","year":"2025","unstructured":"Yakabe D, Inoue S, Sakamoto K et al (2025) Efficacy of sinus rhythm maintenance after catheter ablation for atrial fibrillation in patients with transthyretin amyloid cardiomyopathy. Heart Rhythm 22:e1221\u2013e1229. https:\/\/doi.org\/10.1016\/j.hrthm.2025.04.020","journal-title":"Heart Rhythm"},{"key":"10679_CR13","doi-asserted-by":"publisher","first-page":"euae155","DOI":"10.1093\/europace\/euae155","volume":"26","author":"H Kanazawa","year":"2024","unstructured":"Kanazawa H, Takashio S, Hoshiyama T et al (2024) Clinical outcomes of catheter ablation for atrial fibrillation, atrial flutter, and atrial tachycardia in wild-type transthyretin amyloid cardiomyopathy. Europace 26:euae155. https:\/\/doi.org\/10.1093\/europace\/euae155","journal-title":"Europace"},{"key":"10679_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jcmg.2021.06.022","volume":"15","author":"F Bandera","year":"2022","unstructured":"Bandera F, Martone R, Chacko L et al (2022) Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis. JACC Cardiovasc Imaging 15:17\u201329. https:\/\/doi.org\/10.1016\/j.jcmg.2021.06.022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10679_CR15","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","volume":"5","author":"E Donnellan","year":"2019","unstructured":"Donnellan E, Elshazly MB, Vakamudi S et al (2019) No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. JACC Clin Electrophysiol 5:1473\u20131474. https:\/\/doi.org\/10.1016\/j.jacep.2019.10.013","journal-title":"JACC Clin Electrophysiol"},{"key":"10679_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00399-024-01016-y","volume":"35","author":"M Papathanasiou","year":"2024","unstructured":"Papathanasiou M, Schlender LS, Johnson VL, Wakili R (2024) Arrhythmien bei Amyloidose [Arrhythmias and amyloidosis]. Herzschrittmacherther Elektrophysiol 35:199\u2013204. https:\/\/doi.org\/10.1007\/s00399-024-01016-y","journal-title":"Herzschrittmacherther Elektrophysiol"},{"key":"10679_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.amjcard.2020.12.024","volume":"143","author":"S Thakkar","year":"2021","unstructured":"Thakkar S, Patel HP, Chowdhury M et al (2021) Impact of arrhythmias on hospitalizations in patients with cardiac amyloidosis. Am J Cardiol 143:125\u2013130. https:\/\/doi.org\/10.1016\/j.amjcard.2020.12.024","journal-title":"Am J Cardiol"},{"key":"10679_CR18","doi-asserted-by":"publisher","first-page":"e0301753","DOI":"10.1371\/journal.pone.0301753","volume":"19","author":"P Maury","year":"2024","unstructured":"Maury P, Sanchis K, Djouadi K et al (2024) Catheter ablation of atrial arrhythmias in cardiac amyloidosis: impact on heart failure and mortality. PLoS ONE 19:e0301753. https:\/\/doi.org\/10.1371\/journal.pone.0301753","journal-title":"PLoS ONE"},{"key":"10679_CR19","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jacep.2023.03.013","volume":"9","author":"E Donnellan","year":"2023","unstructured":"Donnellan E, Hussain M, Marrouche N et al (2023) Left atrial strain may predict thrombus formation in patients with transthyretin cardiac amyloidosis. JACC Clin Electrophysiol 9:1418\u20131420. https:\/\/doi.org\/10.1016\/j.jacep.2023.03.013","journal-title":"JACC Clin Electrophysiol"},{"key":"10679_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.jacep.2026.02.008","volume":"12","author":"ID Guarino","year":"2026","unstructured":"Guarino ID, Zghaib T, Nazarian S (2026) AF and stroke risk in wtATTR-CM. JACC Clin Electrophysiol 12:1171\u20131172. https:\/\/doi.org\/10.1016\/j.jacep.2026.02.008","journal-title":"JACC Clin Electrophysiol"},{"issue":"13 Suppl","key":"10679_CR21","doi-asserted-by":"publisher","first-page":"A92","DOI":"10.1016\/j.jacc.2026.02.229","volume":"87","author":"G Ramirez","year":"2026","unstructured":"Ramirez G, Mellado Flores S (2026) Incidence and outcomes of de novo atrial fibrillation in transthyretin amyloid cardiomyopathy patients receiving tafamidis. J Am Coll Cardiol 87(13 Suppl):A92\u2013A93. https:\/\/doi.org\/10.1016\/j.jacc.2026.02.229. Conference abstract","journal-title":"J Am Coll Cardiol"},{"key":"10679_CR22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","volume":"85","author":"DP Judge","year":"2025","unstructured":"Judge DP, Alexander KM, Cappelli F et al (2025) Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 85:1003\u20131014. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.042","journal-title":"J Am Coll Cardiol"},{"key":"10679_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","volume":"151","author":"DP Judge","year":"2025","unstructured":"Judge DP, Gillmore JD, Alexander KM et al (2025) Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial. Circulation 151:601\u2013611. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072771","journal-title":"Circulation"},{"key":"10679_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jacc.2025.09.013","volume":"87","author":"A Masri","year":"2026","unstructured":"Masri A, Judge DP, Ruberg FL et al (2026) Effect of acoramidis on recurrent and cumulative cardiovascular outcomes in ATTR-CM: exploratory analysis from ATTRibute-CM. J Am Coll Cardiol 87:490\u2013501. https:\/\/doi.org\/10.1016\/j.jacc.2025.09.013","journal-title":"J Am Coll Cardiol"},{"key":"10679_CR25","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.jacc.2025.04.008","volume":"85","author":"RM Witteles","year":"2025","unstructured":"Witteles RM, Garcia-Pavia P, Damy T et al (2025) Vutrisiran improves survival and reduces cardiovascular events in ATTR amyloid cardiomyopathy: HELIOS-B. J Am Coll Cardiol 85:1959\u20131970. https:\/\/doi.org\/10.1016\/j.jacc.2025.04.008","journal-title":"J Am Coll Cardiol"},{"key":"10679_CR26","doi-asserted-by":"publisher","first-page":"e14392","DOI":"10.1111\/eci.14392","volume":"55","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Theofilis P, Patoulias D et al (2025) Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: systematic review and meta-analysis. Eur J Clin Invest 55:e14392. https:\/\/doi.org\/10.1111\/eci.14392","journal-title":"Eur J Clin Invest"},{"key":"10679_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","volume":"133","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Sperry BW, Gabrovsek A et al (2020) Digoxin use in cardiac amyloidosis. Am J Cardiol 133:134\u2013138. https:\/\/doi.org\/10.1016\/j.amjcard.2020.07.034","journal-title":"Am J Cardiol"},{"key":"10679_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","volume":"25","author":"E Muchtar","year":"2018","unstructured":"Muchtar E, Gertz MA, Kumar SK et al (2018) Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid 25:86\u201392. https:\/\/doi.org\/10.1080\/13506129.2018.1449744","journal-title":"Amyloid"},{"key":"10679_CR29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.hroo.2025.05.008","volume":"6","author":"AM Petzl","year":"2025","unstructured":"Petzl AM, Oranefo J, Oraii A et al (2025) Outcomes in patients with cardiac amyloidosis undergoing catheter ablation for atrial arrhythmias. Heart Rhythm O2 6:1088\u20131096. https:\/\/doi.org\/10.1016\/j.hroo.2025.05.008","journal-title":"Heart Rhythm O2"},{"key":"10679_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jacep.2025.09.029","volume":"12","author":"M Tan","year":"2026","unstructured":"Tan M, Vignarajah A, Teo Y et al (2026) Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation in cardiac amyloidosis. JACC Clin Electrophysiol 12:325\u2013331. https:\/\/doi.org\/10.1016\/j.jacep.2025.09.029","journal-title":"JACC Clin Electrophysiol"},{"key":"10679_CR31","doi-asserted-by":"publisher","first-page":"e043049","DOI":"10.1161\/JAHA.125.043049","volume":"14","author":"A Aimo","year":"2025","unstructured":"Aimo A, Nesti M, Vergaro G et al (2025) Cardiac resynchronization therapy, remodeling, and outcome in patients with amyloid transthyretin cardiomyopathy. J Am Heart Assoc 14:e043049. https:\/\/doi.org\/10.1161\/JAHA.125.043049","journal-title":"J Am Heart Assoc"},{"key":"10679_CR32","doi-asserted-by":"publisher","first-page":"26948","DOI":"10.31083\/RCM26948","volume":"26","author":"Q Nong","year":"2025","unstructured":"Nong Q, Liang S, Zhu W, Chen Y, Zhang T (2025) Direct oral anticoagulants vs. vitamin K antagonists for atrial fibrillation in cardiac amyloidosis: a systematic review and meta-analysis. Rev Cardiovasc Med 26:26948. https:\/\/doi.org\/10.31083\/RCM26948","journal-title":"Rev Cardiovasc Med"},{"key":"10679_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.rec.2022.08.001","volume":"76","author":"IJ Amat-Santos","year":"2023","unstructured":"Amat-Santos IJ, Delgado-Arana JR, Cruz-Gonz\u00e1lez I et al (2023) Cardiac amyloidosis and left atrial appendage closure. The CAMYLAAC study. Rev Esp Cardiol (Engl Ed) 76:503\u2013510. https:\/\/doi.org\/10.1016\/j.rec.2022.08.001","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10679_CR34","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/jce.16308","volume":"35","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, Torlapati PG, La Fazia VM et al (2024) Best anticoagulation strategy with and without appendage occlusion for stroke-prophylaxis in postablation atrial fibrillation patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 35:1422\u20131428. https:\/\/doi.org\/10.1111\/jce.16308","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10679-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10679-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10679-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:21:46Z","timestamp":1789359706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10679-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10679"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10679-3","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"6 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a review and does not contain any new studies with human participants or animals performed by the authors.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.M.A. has received consulting fees from Alexion\/AstraZeneca, Alnylam, Bayer, BridgeBio, Novo Nordisk, and Pfizer. The remaining authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During manuscript preparation and revision, generative artificial intelligence tools were used to assist with drafting and language editing, stylistic refinement, organization of selected sections, bibliographic verification against primary sources, and development of the conceptual figure. The scientific content, clinical interpretation, and conclusions of this review are those of the authors. All numerical data, references, and final wording were independently reviewed and approved by the authors, who take full responsibility for the content of the manuscript. No generative artificial intelligence tool was listed as an author.","order":5,"name":"Ethics","label":"Use of generative artificial intelligence","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Alexander has received consulting fees from Alexion\/AstraZeneca, Alnylam, Bayer, BridgeBio, Novo Nordisk, and Pfizer. Drs. Pe\u00f1ate, Henriquez Italin, and Dzebu have no conflicts of interest or financial ties to disclose.","order":6,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"106"}}